Abstract
Purpose
To evaluate outcomes of intravitreal injection of bevacizumab for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhages (VH or RH).
Methods
This is a prospective interventional case-series. Fourteen eyes of eight premature infants with severe ROP associated with vitreous or retinal hemorrhage were consecutively included. In eight eyes, VH and/or RH precluding complete laser ablation developed at the time of laser treatment. In six eyes, VH developed early after laser ablation. All participants underwent intravitreal injection of 0.625 mg (0.025 ml) bevacizumab immediately after diagnosis of VH or RH. Follow-up examinations were performed at days 1, 3, 7, and 14, and 1, 2 and 3 months after injection. Main outcome measure was the absence of unfavorable structural outcomes.
Results
Mean gestational age was 27.6 weeks (range, 26–29 weeks) and mean birth weight was 1047 g (range, 780–1500 g). Mean gestational age at the time of injection was 35.4 weeks (range, 32–38 weeks). In all eyes, plus disease disappeared completely within 2 weeks and VH and/or RH was absorbed at last follow-up. None of the eyes developed unfavorable structural outcomes. No eyes needed additional injection or laser treatment. No major systemic or ocular complications were observed.
Conclusion
In this small series of patients, intravitreal injection of bevacizumab was effective for treatment of severe retinopathy of prematurity associated with vitreous or retinal hemorrhage.
Similar content being viewed by others
References
Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity. Results of The Early Treatment for Retinopathy of Prematurity Randomized Trial. Arch Ophthalmol 121:1684–1696
Azuma N, Ishikawa K, Hama Y, Hiraoka M, Suzuki Y, Nishina S (2006) Early vitreous surgery for aggressive posterior retinopathy of prematurity. Am J Ophthalmol 142:636–643
Micelli Ferrari T, Furino C, Lorusso VV, Dammacco R, Sborgia G, Sborgia L, Besozzi G (2007) Three-port lens-sparing vitrectomy for aggressive posterior retinopathy of prematurity: early surgery before tractional retinal detachment appearance. Eur J Ophthalmol 17:785–789
Hutcheson KA, Nquyen ATQ, Reslan MW, Ellish NJ, Steidl SM (2003) Vitreous hemorrhage in patients with high-risk retinopathy of prematurity. Am J Ophthalmol 136:258–263
Kim MJ, Kim S, Yu YS (2008) The risk for retinal detachment associated with hemorrhages pre and postlaser treatment in retinopathy of prematurity. Retina 28:1451–1457
Vinekar A, Trese MT, Capone A Jr, Photographic Screening for Retinopathy of Prematurity (PHOTO-ROP) Cooperative Group (2008) Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. Am J Ophthalmol 145:548–555
Sonmez K, Drenser KA, Capone A Jr, Trese MT (2008) Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 115:1065–1070
Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N (2000) Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 156:1337–1344
Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495–511
Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606
Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278
Mintz-Hittner HA, Kuffel RR (2008) Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28:831–838
Quiroz-Mercado H, Martinez-Castellanos MA, Hermamdez-Rojas ML, Salazar-Teran N, Chan RV (2008) Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 28:S19–S25
Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727–1730
Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, Johnson RA, Puliafito CA (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28:S13–S18
Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K (2007) Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 55:75–76
Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, Fujikado T (2008) Efficacy of intravitreal injection of Bevacizumab for severe retinopathy of prematurity: A pilot study. Br J Ophthalmol 92:1450–1455
Micieli JA, Surkont M, Smith AF (2009) A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 148:536–543
Schwarz Q, Gu C, Fujisawa H, Sabelko K, Gertsenstein M, Nagy A, Taniguchi M, Kolodkin AL, Ginty DD, Shima DT, Ruhrberg C (2004) Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve. Genes Dev 18:2822–2834
Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53–67
Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chévez-Barrios P (2008) Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 126:1161–1163
Mintz-Hittner HA, Best LM (2009) Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr 21:182–187
An International Committee for Classification of Retinopathy of Prematurity (2005) The International Classification of Retinopathy of Prematurity. Arch Ophthalmol 123:991–999
Parvaresh MM, Modarres M, Falavarjani KG, Sadeghi K, Hammami P (2009) Transscleral diode laser retinal photocoagulation for the treatment of threshold retinopathy of prematurity. J AAPOS 13:535–538
Chen J, Smith LE (2007) Retinopathy of prematurity. Angiogenesis 10:133–140
Löfqvist C, Andersson E, Sigurdsson J, Engström E, Hård AL, Niklasson A, Smith LE, Hellström A (2006) Longitudinal postnatal weight and insulin-like growth factor 1 measurements in the prediction of retinopathy of prematurity. Arch Opthalmol 124:1711–1718
Kychenthal A, Dorta P, Katz X (2006) Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 26:S11–S15
Coats DK, Miller AM, Hussein MA, McCreery KM, Holz E, Paysse EA (2005) Involution of retinopathy of prematurity after laser treatment: factors associated with development of retinal detachment. Am J Ophthalmol 140:214–222
Coats DK (2005) Retinopathy of prematurity involution, factors predisposing to retinal detachment, and expected utility of preemptive surgical intervention. Trans Am Ophthalmol Soc 103:281–312
Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M, Pieramici DJ, Berrocal MH, Sanchez JG (2007) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216
Honda S, Hirabayashi H, Tsukahara Y, Negi A (2008) Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 246:1061–1063
Avery RL (2009) Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern. J AAPOS 13:329–331
Author information
Authors and Affiliations
Corresponding author
Additional information
Financial Support
Eye research center, Iran University of Medical Sciences
Financial relationship exists with the organization that sponsored the research
Conflict of interest
No authors have any financial/conflicting interests in the products mentioned in the article
Authors have had full control of all primary data and they agree to allow Graefes Archive for Clinical and Experimental Ophthalmology to review their data upon request.
Rights and permissions
About this article
Cite this article
Nazari, H., Modarres, M., Parvaresh, M.M. et al. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 248, 1713–1718 (2010). https://doi.org/10.1007/s00417-010-1430-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-010-1430-x